ArticleIndian heart journal2018
Baseline C-reactive protein levels and prognosis in patients with infective endocarditis: A prospective cohort study.
Article in Indian heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Clinical Prognosis of Right-Sided Infective Endocarditis not Associated with Cardiac Devices or Intravenous Drug use: a Cohort Study and Meta-Analysis.Scientific reports · 2020Pooled it
- Hypocholesterolemia as a predictor of mortality in infective endocarditis.Internal and emergency medicine · 2026Observational
- Review
- Optimal surgical timing for non-urgent surgery patients with active infective endocarditis.Nagoya journal of medical science · 2025Article
- Embolic risk management in infective endocarditis: predicting the 'embolic roulette'.Open heart · 2025Review
- Clinical Features and Patient Outcomes in Infective Endocarditis with Surgical Indication: A Single-Centre Experience.Journal of cardiovascular development and disease · 2024Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- C-reactive protein and procalcitonin use in adults in low- and middle-income countries: a narrative review.JAC-antimicrobial resistance · 2023Review
- A New Clinical Prediction Rule for Infective Endocarditis in Emergency Department Patients With Fever: Definition and First Validation of the CREED Score.Journal of the American Heart Association · 2023Observational
- Prognostic implications of ultra-short heart rate variability indices in hospitalized patients with infective endocarditis.PloS one · 2023Article
- Sex-Specific Risk Factors for Short- and Long-Term Outcomes after Surgery in Patients with Infective Endocarditis.Journal of clinical medicine · 2022Article
- Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis.Journal of clinical medicine · 2022Article
- Infective endocarditis in paediatric population.European journal of pediatrics · 2021Review
- Normal procalcitonin, C-reactive protein, and negative blood cultures in infective endocarditis with a massive residual vegetation: a case report.European heart journal. Case reports · 2021Article
- Neurological complications in children with infective endocarditis: Incidence, risk factors, and outcome: A 10-year single-center experience.International journal of pediatrics & adolescent medicine · 2021Article
- Comparison of outcome between blood culture positive and negative infective endocarditis patients undergoing cardiac surgery.Journal of cardiothoracic surgery · 2021Article
- Infective endocarditis complicated by embolic events: Pathogenesis and predictors.Clinical cardiology · 2021Review
- C-Reactive Protein at Hospital Discharge and 1-Year Mortality in Acute Infective Endocarditis: A Prospective Observational Study.Frontiers in cardiovascular medicine · 2021Article
- Infective Endocarditis: Preliminary Results of a Cohort Study in the Southern Italian Population.Cureus · 2020Article
- Clinical profile and one-year outcomes of patients with mural infective endocarditis: - A tertiary care centre study based on data from a seven-year registry.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly diagnosis and risk-stratification among infective endocarditis (IE) patients are limited by poor microbiological yield and inadequate characterization of vegetations. A simple tool that can predict adverse outcomes in the early phase of management is required.
aimTo study the prognostic value of C-reactive protein (CRP) levels at admission and its role in predicting various clinical outcomes.
methodsIn a prospective study of consecutive IE patients diagnosed by modified Duke's criteria, we measured the peak levels of CRP and erythrocyte sedimentation rate (ESR) in the first 3 days of admission and correlated it with in-hospital mortality, six-month mortality, embolic phenomena and the need for urgent surgery. Predefined laboratory-microbiological sampling protocols and antibiotic-initiation protocols were followed. Receiver-operating-characteristics curves were generated to identify a reliable cut-off for CRP in predicting various outcomes.
resultsOut of 101 patients who were treated, 85 patients had 'definite' IE. Blood cultures were positive in 55% (n = 39); and Staphylococcus species was the most common organism. Major complications occurred in 74.1% (n = 63) and in-hospital mortality was 32.9% (n = 28). Mean ESR and CRP levels were 102 ± 31 mm/h and 51 ± 20 mg/l, respectively. In multivariable analysis, high CRP levels were independently predictive of mortality, major complications, embolic events and need for urgent surgery. A CRP >40 mg/l predicted adverse outcomes with a sensitivity of 73% and specificity of 99%.
conclusionThe study shows that baseline CRP level in the first 3 days of admission is a strong predictor of short term adverse outcomes in IE patients, and a useful marker for early risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.